Journal of Cheminformatics

BackgroundAdverse drug-drug interactions (DDIs) cause preventable hospitalizations, but exhaustive experimental screening of all drug pairs is infeasible. Many computational predictors rely on SMILES or other molecular representations, limiting their direct applicability to biologics and other non-small-molecule therapeutics. We present a structure-agnostic framework that combines semantic representations derived from Medical Subject Headings (MeSH) with graph-derived topology from a Drug-Target-Protein knowledge graph constructed from DrugBank and UniProt. We further investigate how variation in MeSH annotation depth affects predictive performance. ResultsDrugs are grouped according to their deepest MeSH annotation level (Low, Mid, or Deep), and performance is evaluated across the resulting interaction categories in transductive and inductive settings. The Intermediate ontology scope (Low+Mid) provides the most stable performance, while adding Deep-level terms offers limited and inconsistent benefit. Lightweight topological descriptors are integrated with MeSH features through instance-wise, dimension-specific latent-space gating, using curated reliable-negative pairs for supervision. Fusion improves mean performance over the MeSH-only baseline across all six categories in the transductive setting. Under induction, the clearest gains occur for Low-Low interactions ({Delta}AUROC = 0.056;{Delta} F1 = 0.137) and Low-Mid interactions ({Delta}AUROC = 0.077;{Delta} F1 = 0.114). ConclusionsMeSH annotation depth is associated with systematic variation in DDI prediction performance that aggregate evaluation can obscure. Graph-derived topology is particularly beneficial when ontology annotations are shallow. The framework provides a common, structure-agnostic representation compatible with both small-molecule and biologic therapeutics and supports first-pass DDI prioritization for subsequent expert assessment.

Machine learning (ML) models for molecular property prediction are increasingly deployed in drug discovery, yet their adoption in real-world scenarios requires an understanding of the conditions in which a model succeeds or fails. While standardized benchmarks are powerful instruments to measure and unlock progress in ML research, they should not be blindly treated as the end goal. Especially static and retrospective benchmarks, in which no true unknown test set is employed, limit our ability to robustly validate a model's performance. Building on the collective expertise of a cross-industry consortium, we present a model validation framework consisting of five recommendations that would enable the community to move beyond aggregate metrics toward understanding where and why molecular property prediction models fail. We connect evaluation choices to real-world applications and case studies encountered in pharmaceutical research. The framework proposes splitting strategies that mimic realistic distribution shifts and expose common failure modes. We apply the recommended framework to a recently released dataset of absorption, distribution, metabolism, and excretion (ADME) properties. Across two complementary model algorithms, our case studies reveal four distinct failure modes (extrapolation, interpolation, representation, and evaluation), showing that model errors arise not only from distribution shift but also from limitations in molecular representations. Our results show that commonly used evaluation protocols can significantly overestimate performance and may not detect important model failure modes. All software and data are released via https://github.com/srijitseal/polaris.

Accurate ADMET prediction is essential for prioritizing compounds before costly experimental validation, yet ADMET tasks are highly heterogeneous. Properties such as solubility, permeability, protein binding, clearance, transporter activity and toxicity are governed by different molecular signals, ranging from local functional groups and physicochemical descriptors to bonded topology and three-dimensional geometry. Consequently, a single molecular representation or backbone is unlikely to be optimal across all ADMET tasks. We present Trimole-Hybrid, a task-wise multimodal framework that addresses ADMET heterogeneity by selecting or combining predictors built from complementary molecular representations. Trimole-Hybrid constructs a candidate pool of SMILES-, graph-, geometry-sensitive EPT/3D- and chemical descriptor-based predictors. For each task, Trimole-Hybrid selects the best-performing predictor to obtain the final prediction. On 22 Therapeutics Data Commons ADMET benchmarks, Trimole-Hybrid exceeded the public TDC top-1 methods on 10 tasks and ranked within the top 10 for 21 tasks. Ablation studies confirmed the contribution of both complementary multimodal molecular representations and task-specific ensemble strategies. In two small-molecule case studies, Trimole-Hybrid shows sensitivity to changes in essential functional motifs, suggesting its ability to capture ADMET-relevant molecular substructures.

High-quality molecular datasets are essential for reliable machine learning in cheminformatics and bioinformatics, yet dataset quality is rarely assessed systematically and its relationship with downstream model performance remains poorly understood. Here, we present MolJam, an open-source framework for quantitative assessment of molecular dataset quality across five dimensions-structural integrity, data quality, experimental information quality, chemical space coverage, and data distribution-using 12 standardized metrics. Application of MolJam to 11 MoleculeNet and eight ChEMBL-derived datasets revealed widespread and heterogeneous quality issues, including undefined stereochemistry in up to 70.72% of molecules, inconsistent molecular representations, and contradictory labels. We next asked whether improving these quality metrics necessarily improves machine learning performance. Refinement of the ESOL and Lipophilicity datasets increased their MolJam quality scores but produced mixed effects on predictive performance, suggesting a competing influence of reduced dataset size. Controlled ablation experiments further demonstrated that both dataset quality and data quantity contribute to model performance and, notably, that retaining molecules with incomplete stereochemical information can outperform their removal when the resulting gain in data quantity offsets the quality penalty. Thus, molecular dataset curation cannot be reduced to maximizing data cleanliness alone but requires balancing multiple dimensions of data quality against information loss. MolJam provides a standardized framework for diagnosing molecular dataset limitations, comparing benchmark quality, and quantitatively evaluating how data curation decisions influence downstream machine learning.

Protein-ligand interaction diagrams are a routine part of structural and medicinal chemistry, but the tools that produce them tend to force a choice: comprehensive detection with tabular output, publication-quality figures behind a licence, or a scripting environment that assumes expertise. PandaMap (Protein AND ligAnd interaction MAPper) is an open-source Python package that produces a 2D interaction diagram, an interactive 3D viewer, a text report, a machine-readable CSV, and a four-panel graphical summary from a single command. It reads PDB, mmCIF and PDBQT files, detects 15 interaction classes using crystallographically validated distance thresholds, and depends only on NumPy, Matplotlib, BioPython and Requests; RDKit improves the 2D ligand layout when present but is not required. Hydrogen bonds are filtered on the true D-H{middle dot} {middle dot} {middle dot} A angle when the structure contains explicit hydrogens, matching PLIPs 100{whitebullet} criterion on the same evidence, and on distance alone otherwise, with the provenance of each measurement recorded. We benchmarked the package on three complexes chosen for different chemistry: enolase with a phosphonate transition-state analogue (PDB 1ELS), the EGFR kinase with erlotinib (1M17), and aldose reductase with IDD594 (1US0). PandaMap recovers the contacts these structures are known for, including the EGFR hinge hydrogen bond to MET769 and the IDD594 bromine{middle dot} {middle dot} {middle dot} THR113 halogen bond, both at distances identical to PLIPs. All detection thresholds, scoring weights and the exact commands used are given in the Supplementary Information, and the release carries a regression suite covering each interaction class. PandaMap 4.3.0 is available on PyPI under the MIT licence.

Drug discovery (DD) is a complex, time-consuming, and resource-intensive process that involves the identification of therapeutic targets, selection of bioactive compounds, and extensive experimental validation. The discovery of promising therapeutic compounds from large libraries of phytochemicals and synthetic molecules remains a major challenge in modern drug development. Screening millions of compounds through conventional experimental approaches requires substantial time, cost, and computational resources. In recent years, in- silico molecular docking has emerged as an important computational approach for predicting interactions between small molecules and target proteins, thereby helping researchers prioritize promising compounds for further investigation. Several molecular docking webservers, including iScreen, SwissDock, CB-Dock2, DockThor, and MTiOpenScreen, have been developed to support virtual screening studies. However, many currently available platforms still face some important limitations. Most existing tools lack integrated repositories of medicinal plant-derived phytochemicals and organism-derived bioactive compounds, automated mapping between plants and their associated phytochemicals, and flexible ligand retrieval using chemical names, SMILES strings, PubChem CIDs, or drug names. In addition, many platforms require extensive manual protein and ligand preparation, provide limited support for AlphaFold-predicted protein structures, and lack efficient large-scale multi-target virtual screening. Most existing docking platforms offer limited support for interactive inspection of docked protein-ligand complexes, often requiring users to download the results and analyse them using external molecular visualization software. To address these limitations, we developed FlexAutoDock, an automated cloud-based molecular docking platform that provides a unified environment for protein-ligand docking and large-scale virtual screening. Unlike existing web servers, FlexAutoDock integrates curated repositories of medicinal plant- derived phytochemicals, organism-derived bioactive compounds, and synthetic compounds from the ZINC database while supporting flexible ligand acquisition through medicinal plant or organism selection, chemical names, SMILES strings, PubChem CIDs, and drug-name queries. The platform further streamlines the docking workflow through automated protein structure retrieval from the Protein Data Bank and AlphaFold databases, receptor and ligand preparation, chain-specific protein selection, blind and site-specific docking, interactive visualization of predicted protein-ligand complexes, and scalable multi-target virtual screening. The resulting platform enables rapid, flexible, and large-scale virtual screening while simplifying the molecular docking workflow, providing researchers with an accessible computational resource for accelerating early-stage drug discovery. FlexAutoDock offers a fast, reliable, and accessible computational platform for molecular docking and virtual screening, freely available to the scientific community at http://103.99.177.82:3000/.

Molecules generated by deep learning models are often difficult to synthesize. Their synthetic accessibility can be improved with automated retrosynthetic analysis, which allows for identifying synthons. However, synthons in a SMILES can be scattered throughout the string depending on the path taken through the molecular graph used to generate the SMILES. We tested whether the ensemble of possible SMILES for a molecule can be used to generate a concatenable ordered sequence of string fragments (blocks) from SMILES that match potential synthons obtained through automated retrosynthetic analysis. We found that exhaustively sampling the SMILES space of a molecule improves the coverage of retrosynthetic breaks. We achieved full coverage of retrosynthetic bonds in string form for 85\% of the 1.9 million molecules in the MOSES dataset. Doing so allowed us to test our block SMILES in an unconditional de novo drug design test case with MolGPT and Monte Carlo Tree Search (MCTS). We found that using blocks as an LLM's token did degrade MolGPT performance due to the curse of dimensionality. However, using the SMILES selected by our blocking algorithm with the default SMILES tokenizer improved the reproduction of physico-chemical properties of samples and also improved uniqueness, novelty, and validity. The MCTS outperforms our MolGPT models in terms of validity and novelty. However, samples generated by the MCTS had physico-chemical properties that were further away from the MOSES baseline than the samples produced by molGPT, with an improved distribution of quantitative estimation of drug-likeness (QED).

Generative artificial intelligence is accelerating molecular design, yet the relative suitability of available models for different targets and stages of preclinical drug discovery remains unclear. Here we benchmarked 12 molecular generation and optimization methods across 176 curated protein-ligand systems spanning diverse therapeutic target classes, with experimentally validated ligands providing reference chemical space. The evaluated methods encompassed pocket-conditioned 3D generation, diffusion and flow-based modeling, autoregressive construction, reference-conditioned optimization and synthesis-aware design. Performance was assessed using operational robustness, chemical validity, uniqueness, molecular and scaffold diversity, quantitative estimate of drug-likeness, synthetic accessibility, docking, physicochemical and ADMET properties, and computational resource requirements. The results revealed architecture-dependent trade off such as receptor-conditioned methods exploited binding-pocket geometry, flow-based approaches enabled efficient sampling, reference-conditioned methods favored analogue generation, and synthesis-aware approaches improved chemical feasibility, but no method consistently optimized all criteria. To address the functional potential of generated molecules, we further developed a state-aware functional classifier (SAFC) that integrates molecular dynamics derived receptor ensembles, ensemble docking and protein ligand interaction graphs. SAFC provided dynamics-aware functional activity rankings for generated molecules that were partly complementary to docking, drug-likeness and synthetic accessibility scores. These findings support hybrid, stage specific deployment of generative models rather than reliance on any single architecture or evaluation metric. This study provides practical guidelines for generative AI based preclinical drug development processes.

Molecular docking and co-folding engines are widely used to prioritize compounds for wet-lab validation, yet their accuracy is known to vary substantially across protein targets for reasons that remain only qualitatively understood. Here we benchmark six docking and co-folding engines (RevDock, DiffDock, Boltz2, AutoDock-GPU, rDock, and PandaDock) across 14 protein families, evaluating scoring power, ranking power, docking power, and physical validity. Rather than treating engine performance as protein-family-specific, we classify all 14 families into six mechanistic groups according to which of four scoring-function simplifications, rigid receptor, pairwise additivity, fixed point charges, and implicit solvent, is most severely stressed by that familys binding site. This framework helps explain, rather than simply describe, where each engine succeeds or fails: RevDocks CNN rescoring layer mitigates the pairwise additivity and fixed-charge limitations relative to physics-only scoring, achieving the highest overall pose accuracy (73.3% of poses [≤] 2.0 [A] RMSD), while Boltz2s sequence-based co-folding bypasses the rigid-receptor assumption and achieves comparable affinity correlation (mean Pearson r {approx} 0.60 for both engines). PandaDock, run with expanded conformational sampling, matches RevDock on pose accuracy (72.1% of poses [≤] 2.0 [A], lowest median RMSD at 0.96 [A]) and exceeds AutoDock-GPU on affinity correlation (mean r = 0.460), indicating that the performance of a physics-based scoring function is limited as much by search adequacy as by the scoring function itself. These results suggest that engine selection for a docking or co-folding campaign should be guided less by an engines aggregate benchmark ranking and more by which of these four structural and physical characteristics dominate the target of interest.

Scientific agents can produce plausible answers while remaining unable to establish whether the computation behind an answer is executable, recoverable, or reproducible. We present BloClaw, an AI4S workstation built around a simple principle: a scientific agent should know what it can do, show how it did it, and state what remains unvalidated. Each capability declares an execution state, input constraints, dependencies, expected outputs, and scientific limitations. Natural-language requests are translated into structured tasks, validated against this registry, executed through scientific tools, and recorded in a provenance-aware Living Lab Notebook. The system is designed to detect invalid inputs, failed tool calls, missing dependencies, and remote timeouts, and to route them to repair, retry, or escalation. The implemented and tested scope comprises RDKit-based molecular property and rule screening, protein structure analysis, docking-pose inspection, 3D visualization, and structured reporting. We demonstrate the workflow on a PubChem-retrieved osimertinib structure and a supplied 6LU7 docking artifact: the former yields deterministic descriptors (molecular weight 499.619 Da, cLogP 4.5098, TPSA 87.55 A^2), while the latter contains 2,387 protein ATOM records, 309 residues, and nine pose records. These examples are workflow demonstrations, not efficacy or affinity studies. Beyond retrospective prediction, the manuscript specifies a prior-minimized constructive mode in which a desired function is compiled into explicit physical, chemical, and systems constraints, candidate mechanisms are simulated, and observations are reintroduced for calibration and falsification; this is a proposed extension rather than a result of the present case studies. We describe an evaluation protocol that compares BloClaw with a standard single-agent workflow and fixed-script execution using task completion, scientific correctness, recovery success, provenance completeness, reproducibility, human review time, latency, and cost. This manuscript reports the system design, verified capability boundary, deterministic software artifacts, and a reproducible evaluation protocol; it does not claim benchmark improvements before those experiments are run. BloClaw is an execution and accountability layer for AI-assisted research, complementing expert review and experimental validation rather than replacing them.

Lead optimization, the systematic refinement of therapeutic compounds through iterative structural modification, faces a dual challenge in modern drug discovery: navigating astronomically vast molecular design spaces while balancing conflicting demands on potency, pharmacokinetics, and safety. We present MASCOT (Multi-Agent SearCh for molecular OpTimization), a role-specialized multi-agent framework for molecular optimization. Integrated with a chemically constrained graph-editing search, MASCOT coordinates three specialized agents: a trade-off agent that reprioritizes competing objectives, a strategy agent that adapts how molecular edits are proposed, and a reflection agent that distills lessons from previous decisions. Computational experiments showed that MASCOT achieved the best performance over competing methods on six benchmark settings. On the SARS-CoV-2 main protease task, its mean docking-score improvement was 3.6 times that of the strongest baseline. Applied to the clinically used anesthetic remimazolam (RM), MASCOT prioritized RM-1, which showed a shorter liver microsomal half-life, higher brain exposure, and a larger therapeutic index than RM. Subsequent derivative design yielded RM-7. Extensive animal studies established RM-7 as a rapid-recovery intravenous anesthetic candidate with greater potency, faster functional recovery, a wider safety margin, and preserved flumazenil reversibility. These results demonstrate that multi-agent coordination can link adaptive molecular search to medicinal chemistry and experimental pharmacology.

An accurate and tractable approximation of the single-point mutation-induced change in protein thermodynamic stability, denoted by DDG, is critical for understanding the genotype-phenotype relationship. Several computational methods have been proposed for this problem; however, limited and error-prone training data and the difficult-to-predict magnitude of structural perturbations make this a challenging task. Consequently, the computational predictors proposed throughout the past decade incrementally improved prediction performance by proposing novel features, combining existing features, task-adapted neural network architectures, loss functions, data augmentation techniques, and pre-training procedures. In this work, we propose PMPNN-DDG, a Random Forest-based DDG prediction model, trained on a novel set of interpretable features extracted from the recently proposed message-passing neural network-based fixed backbone protein design model, ProteinMPNN. On the S669 independent test set, PMPNN-DDG achieves rF +R = 0.64 and RMSE = 1.45, outperforming all compared baseline methods across the reported evaluation measures. On the Ssym independent test set, it achieves rF +R = 0.81, rF -R = -0.99, and RMSE = 1.10, showing competitive performance relative to the compared baselines. PMPNN-DDG is publicly available at https://github.com/dRanger666/PMPNN-DDG.

Proteins are dynamic molecules capable of adopting multiple conformations. However, AlphaFold2 predominantly generates models around a single conformation, usually representing a ligand-bound state. To address this limitation, we developed AlphaConformers, a structure-guided pipeline that steers AlphaFold2 toward alternative conformations. It is based on the idea that protein structure databases can capture the structural space accessible to members of a protein family. Given a target protein, AlphaConformers retrieves structures from structurally similar proteins. These structures are organized into structure-based alignments and template sets, which are supplied to AlphaFold2 as conformational hypotheses. The resulting models are clustered and filtered, facilitating their analysis. Evaluated on a curated benchmark of 88 proteins with known ligand-bound and unbound conformations, AlphaConformers expanded AlphaFold2 conformational sampling and recovered alternative states missed by AlphaFold2 and other state-of-the-art methods. AlphaConformers ranked first for modelling subtle conformational changes commonly observed between ligand-bound and unbound states. These results show that structural information from protein databases can be leveraged to steer AlphaFold2 toward alternative conformations.

We present PandaDock, an open-source molecular docking platform implementing flexible-ligand conformational search with analytic gradients, a precomputed affinity grid engine, specialized modules for induced-fit, metal-coordination and tethered docking, and an SE(3)-equivariant graph neural network scoring function trained at scale. Ligand flexibility is represented as a torsion tree and pose parameters are optimized by Monte Carlo with Metropolis acceptance refined by L-BFGS, with rotational gradients obtained in closed form through the derivative of the SO(3) exponential map rather than by finite differences. Affinity grids are built by a blocked neighbor-selection scheme that is exact and 5.6-9.7x faster than dense evaluation, and may be cached across ligands sharing a receptor and site, reducing a six-ligand series from 29.3 s to 10.4 s. On 814 protein-ligand complexes spanning 14 target families, PandaDock recovers a pose within 2 Angstroms of the crystal geometry in 33.7% of cases at rank 1 and in 57.0% of cases within the returned ensemble. The GNN scoring function is trained on 741,706 co-folded complexes from SAIR under target-disjoint splits, reaching a Pearson r of 0.407 on 90,219 held-out complexes and transferring to 202 independent crystal structures with measured Ki, Kd, IC50 or EC50 at r = 0.467. We report the model against three controls, a target-mean predictor, a ligand-descriptor-only baseline, and within-target correlations, and document both where it performs and where it does not, including its unsuitability for pose rescoring. On an independent 30-compound series against a single GABAA receptor target, PandaDock's empirical scoring function ranks 8th of 25 methods evaluated, ahead of every AutoDock Vina and Vinardo configuration tested, while the GNN scores below Vina, consistent with the within-target ceiling identified on SAIR. At full scale on the PDBbind v2020 refined set (n = 4,640, native crystal poses), the fully independent SAIR model reaches r = 0.531, and a dedicated model trained on PDBbind alone under a target-disjoint split reaches r = 0.690 on its own held-out test complexes, the strongest evidence in this work that PandaDock's affinity predictions generalize. PandaDock is distributed under an open-source license at https://github.com/pritampanda15/PandaDock with a complete command-line interface and a reproducible benchmarking harness.

G protein-coupled receptor (GPCR) allosteric modulators (AMs) offer significant therapeutic advantages over orthosteric drugs, yet structure-based virtual screening lacks validated protocols accounting for the conformational complexity of GPCR allosteric sites. We benchmark docking protocols using PDB experimental structures and structural ensembles derived from Gaussian accelerated Molecular Dynamics (GaMD) simulations across four Class A GPCRs (including the muscarinic M2 and M4 receptors, the {beta}2-adrenergic receptor, and the C-C chemokine receptor type 2) with four programs (Glide HTVS, AutoDock Vina, DOCK3.8, and Boltz-2) against experimentally validated modulator libraries and property-matched decoys. GaMD ensemble docking improved early AM enrichment across all four targets under at least one program. Glide ensemble docking was the only protocol to consistently improve early AM recovery across all four targets, ranking known actives almost exclusively within the top 0.5% of compounds at CCR2 and improving M2R active recovery nearly 9-fold relative to the PDB structure. GaMD free-energy landscape topology governed ensemble re-ranking strategy selection: population-skewed landscapes favored top binding energy ranking (BEmin) while flat, multi-populated landscapes favored average binding energy ranking (BEavg), and at targets with dominant low-energy states, a single GaMD cluster matched or exceeded full ensemble or PDB performance. Taking the union of top percentile hits identified by both ensemble re-ranking methods, BEmin / BEavg, maximizes chemical diversity at the earliest percentiles. Program-specific scaffold recovery biases further motivated a consensus BEmin / BEavg approach to maximize hit diversity. The Boltz-2 deep-learning program showed minimal sensitivity to GaMD templates and underperformed conventional docking, suggesting its affinity predictions complement rather than replace physics- and empirical-based docking approaches for GPCR AM screening.

Accurately predicting the effects of pharmacogenomic variants is essential for the development of personalized therapeutic strategies, as genetic variability can influence drug response differently across patients. Here, we assessed several computational approaches using a dataset of pharmacogenomic variants with either clinical annotations or functional characterization by deep mutational scanning, compiled from the literature, with an additional focus on CYP2C9, a clinically relevant drug-metabolizing enzyme. Our results show that, despite recent methodological advances, substantial room for improvement remains. In particular, current methods struggle to distinguish gain-of-function variants associated with increased drug clearance and fast-metabolizer phenotypes from neutral variants, whereas loss-of-function variants that reduce drug clearance are predicted more accurately. The integration of structural and evolutionary information appears to be a key strategy for improving performance, with the coevolution-based StructureDCA method achieving the highest accuracy compared with classical genetic variant-effect predictors and recent deep learning approaches, including the pathogenic-variant predictor AlphaMissense and general protein language model-based methods. Finally, our results indicate that computational models can complement in vitro experiments in clinical variant interpretation, as StructureDCA predictions showed better agreement with clinically annotated phenotypes than large-scale deep mutational scanning data in several cases.

BackgroundBiomolecular dataset construction often requires coordinated retrieval from heterogeneous repositories, identifier mapping, cross-reference enrichment, source-specific parsing, and provenance recording. These operations are frequently implemented through project-specific scripts, making acquisition procedures difficult to inspect, reproduce, or adapt across studies. We present SilkRoute, an open-source Python framework that formalizes biomolecular data acquisition as descriptor-defined, source-aware, and provenance-tracked workflows, providing a reproducible foundation for multi-source biomolecular dataset construction. ResultsSilkRoute uses machine-readable YAML descriptors to specify dataset intent, biomolecular modality, workflow mode, query logic, enrichment resources, execution parameters, and export settings. These descriptors drive a common execution model that coordinates primary retrieval and downstream enrichment while preserving source-specific outputs, interaction evidence when available, the original workflow configuration, metadata, and run summaries. We evaluated this model through three representative acquisition scenarios spanning proteins, compounds, and molecular interactions. In the protein-centered workflow, SilkRoute retrieved 2,444 reviewed antimicrobial protein records from UniProt and generated complementary outputs from AlphaFold DB, InterPro, Pathway Commons, and the Protein Data Bank. In the compound-centered workflow, a ChEMBL IC50 query produced 1,445,939 activity records organized into query-defined potency ranges. In the interaction-centered workflow, 2,253 UniProt protein records were expanded with 902,713 BioGRID interaction records and 5,702 STRING interaction-partner records. Across these scenarios, the framework successfully applied the same descriptor-defined acquisition model to distinct biomolecular entity types, retrieval strategies, enrichment paths, and output structures. ConclusionsSilkRoute extends beyond sequence retrieval by providing a reusable acquisition layer for constructing multi-source biomolecular datasets. By separating primary retrieval from enrichment and preserving source-aware outputs together with workflow descriptors and execution metadata, the framework makes acquisition procedures easier to inspect, reproduce, archive, and adapt. SilkRoute does not replace biological curation, label validation, deduplication, partitioning, or benchmarking, but provides structured and traceable acquisition packages that support these downstream processes.

Biophysics is a rapidly advancing field with an incredible breadth of topics. Thus, undergraduate biophysics instructors have to strategize and decide what topics they will cover in their courses. Educational institutions utilize a variety of biophysics textbooks. A common deficiency of each of the existing texts is that it serves well a given set of topics (theory, illustrations, practice problems) and leaves out other areas. A typical example includes good theory and problems for thermodynamics and kinetics while presenting molecular dynamics and various spectroscopic methods in a lacking or outdated way. The authors of this manuscript teach a capstone Biophysical Chemistry three-quarter series (Western Washington University/WWU, Bellingham, WA) which ideally should resonate with the general and major-specific courses the students take within their major at WWU. To achieve this goal and to enrich the traditional lecture-based delivery, the instructors have developed and brought together key pedagogical elements: purpose-built online textbook with a uniform structure of the academic content and practice problems, a study sample (oligopeptide) of biophysical significance with a growing set of experimental and computational data and student-centric in-class activities including computer labs. Our Biophysical series emphasizes concepts and methods of computational structural biology (Molecular Dynamics) and spectroscopic approaches (IR, UV and NMR). Here we describe the details of our integrative approach, summarize key outcomes and chart ways to advance the biophysical chemistry series further. Our textbook can be found through LibreText.

MotivationLigand binding-site similarity search is a crucial step in drug discovery that reduces the conformational search space for docking and other downstream tasks by comparing a target protein against experimentally identified binding sites. Existing methods rely on either direct structural alignment or lossy compression of structural information, producing a trade-off between scalability and precision. ResultsWe propose LEN-Seek, a ligand binding-site search method based on a graph neural network (GNN)-driven variational autoencoder (VAE) that encodes the 3D structural and physicochemical context of a binding site into a probabilistic latent space, enabling similarity search within a low-dimensional vector space. A binding site is modeled as a graph of amino acid residues, with node features adopted from the protein language model, Ankh, and edges encoded as SE(3)-invariant (roto-translational invariant) geometric relationships, thereby avoiding expensive data augmentation or SE(3)-equivariant models. Compared to ProBiS, the purely geometric graph-clique based method, LEN-Seek successfully retrieves a substantial portion of similar binding sites with a roughly 3,400-fold lower per-comparison cost, demonstrating its potential as a scalable approach to template-based ligand binding-site search in large-scale protein structure databases. Supplementary informationSupplementary data are available at Bioinformatics online.

Summary: Prot2Surf is a software tool designed for the characterization and prediction of protein association to surfaces. In this application note, Prot2Surf was tested using catalytic domains of the lytic polysaccharide monooxygenases (LPMOs), interacting with native surfaces. The results show that the software can efficiently analyze key binding features, including protein-surface distances, distances between catalytically reactive atoms, and the orientation angle between surface chains and the protein. These features are essential for distinguishing productive binding poses in these protein-surface systems and for understanding interaction patterns that provide guidance on protein engineering. Prot2Surf performs these analyses within seconds to a few minutes, providing a fast and accessible framework to post-process and characterize protein-surface encounter complexes. Availability and implementation: Prot2Surf, which is written in Fortran90, is documented and freely available as open source on GitHub: https://github.com/TUNNELING-GROUP/Prot2Surf. In order to run Prot2Surf, users should also install the SDA software package which is freely available at https://www.h-its.org/downloads/sda7/.